Insider · CIK 0001237253
Paul Bisaro
director
Files at MYGN (MYRIAD GENETICS INC), ZTS (Zoetis Inc.), Keenova Therapeutics plc. First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | MYGN MYRIAD GENETICS INC | AGrant or award Common Stock | +49,796 | $0.00 | $0 | 89,941 | Jun 6, 2025 |
| Feb 19, 2025 | ZTS Zoetis Inc. | AGrant or award Restricted Stock Unitderivative | +1,596 | $0.00 | $0 | 1,596 | Feb 20, 2025 |
| Feb 8, 2025 | ZTS Zoetis Inc. | MOption exercise Common Stock | +1,225 | - | - | 24,243 | Feb 11, 2025 |
| Feb 8, 2025 | ZTS Zoetis Inc. | MOption exercise Restricted Stock Unitderivative | -1,225 | - | - | 0 | Feb 11, 2025 |
| Feb 6, 2025 | ZTS Zoetis Inc. | MOption exercise Common Stock | +1,236 | - | - | 23,018 | Feb 10, 2025 |
| Feb 6, 2025 | ZTS Zoetis Inc. | MOption exercise Restricted Stock Unitderivative | -1,236 | - | - | 0 | Feb 10, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | MOption exercise Ordinary Shares | +2,507 | - | - | 2,507 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | FTax withholding Ordinary Shares | -489 | - | - | 2,018 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | DDisposition to issuer Restricted Stock Unitsderivative | -2,052 | - | - | 11,626 | Jan 2, 2025 |
| Jan 1, 2025 | - Keenova Therapeutics plc | MOption exercise Restricted Stock Unitsderivative | -2,507 | $0.00 | $0 | 9,119 | Jan 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.